Latest news with #Fangzhou
Globe and Mail
21-07-2025
- Health
- Globe and Mail
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3 rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou and Novo Nordisk Signed Collaboration Memorandum Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin, and Christine Zhou, Novo Nordisk Senior Vice President & President of Region China, attended the signing ceremony. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a 'disease-centered' approach to a 'health-centered' model, providing patients with higher quality and more convenient one-stop healthcare services. Dr. Xie Fangmin remarked, 'We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.' Christine Zhou said, 'With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.' Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the 'Healthy China 2030' strategic objectives. About Fangzhou Inc. Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit
Yahoo
21-07-2025
- Health
- Yahoo
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and and Novo Nordisk Signed Collaboration Memorandum Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin, and Christine Zhou, Novo Nordisk Senior Vice President & President of Region China, attended the signing ceremony. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a 'disease-centered' approach to a 'health-centered' model, providing patients with higher quality and more convenient one-stop healthcare services. Dr. Xie Fangmin remarked, 'We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.' Christine Zhou said, 'With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.' Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the 'Healthy China 2030' strategic objectives. About Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit Media ContactFor further inquiries or interviews, please reach out to:Xingwei Zhao, Associate Director of Public Relations Email: pr@ Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements A photo accompanying this announcement is available at in to access your portfolio
Toronto Star
21-07-2025
- Health
- Toronto Star
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. ('Fangzhou' or the 'Company') ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity.
Hamilton Spectator
21-07-2025
- Business
- Hamilton Spectator
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
BEIJING, July 21, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. ('Fangzhou' or the 'Company') ( a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leveraging its AI application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity. Fangzhou and Novo Nordisk Signed Collaboration Memorandum Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin, and Christine Zhou, Novo Nordisk Senior Vice President & President of Region China, attended the signing ceremony. By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a 'disease-centered' approach to a 'health-centered' model, providing patients with higher quality and more convenient one-stop healthcare services. Dr. Xie Fangmin remarked, 'We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale.' Christine Zhou said, 'With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments.' Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the 'Healthy China 2030' strategic objectives. About Fangzhou Inc. Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit . Media Contact For further inquiries or interviews, please reach out to: Xingwei Zhao, Associate Director of Public Relations Email: pr@ Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements A photo accompanying this announcement is available at
Malaysian Reserve
29-05-2025
- Business
- Malaysian Reserve
Fangzhou Showcases AI-Driven Healthcare Ecosystem at PHARMCHINA as China's Shift to Digital Medicine Accelerates
GUANGZHOU, China, May 29, 2025 /PRNewswire/ — Fangzhou Inc. ('Fangzhou' or the 'Company') ( a leader in Internet healthcare solutions, took center stage at the 4th Annual 'Internet + Pharma' Service Innovation Conference, held during the 90th PHARMCHINA exhibition in Guangzhou, and presented its AI-powered healthcare ecosystem to over 300 industry experts. The event coincided with China's accelerated healthcare digitization efforts, including the recently introduced 2025-2030 Pharmaceutical Industry Digital Transformation Implementation Plan ('Implementation Plan') which emerged from a collaborative effort among seven regulatory bodies, comprising the Ministry of Industry and Information Technology ('MIIT'), the National Health Commission, the Ministry of Commerce, and other key ministries. Fangzhou's founder, chairman, and CEO Dr. Xie Fangmin remarked, 'Our H2H (Hospital-to-Home) smart healthcare ecosystem leverages advanced AI tools that align with China's healthcare industry roadmap and help to improve healthcare accessibility.' AI-enabled Healthcare During the keynote session, Guo Zhi, Senior Vice President of Technology at Fangzhou, shared the latest advancements the Company's AI-driven H2H smart healthcare ecosystem, highlighting its cutting-edge solution to mitigate hallucination risks in medical large language models. He also outlined how AI integration, such as intelligent pre-consultation using its AI assistant, is driving efficiency gains and patient satisfaction across its platform. Guo noted that, 'AI is transforming healthcare from labor-intensive to algorithm-driven', and highlighted Fangzhou's commitment to addressing China's twin challenges of an aging population and rapidly growing healthcare needs. AI Transformation as Strategic Imperative In recent years, China's national policies have placed growing emphasis on AI adoption throughout the healthcare sector, marking a clear shift in regulatory and developmental priorities. The recent Implementation Plan positions AI and digital transformation as core requirements for industry advancement. This policy momentum is driving widespread adoption of smart technologies and reshaping the strategic roadmaps of healthcare enterprises nationwide. Looking ahead, Fangzhou remains committed to advancing its mission by deepening AI integration across diverse healthcare settings. About Fangzhou Inc. Fangzhou Inc. ( is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit About 4th 'Internet + Pharma' Service Innovation Conference The conference brought together over 300 industry representatives, uniting government, industry, academia, research, and medical sectors to jointly explore pathways and opportunities for the pharmaceutical industry's transformation and upgrading. Media ContactFor further inquiries or interviews, please reach out to:Xingwei Zhao Associate Director of Public Relations Email: pr@ Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
